Mining the Dark Matter of the Cancer Proteome for Novel Biomarkers
Ana Paula Delgado,
The post genome era has ushered us into therapeutic target discovery empowering us to mine the genome using
rational approaches. Numerous cancer targets have emerged from the genome project for diagnostics, therapeutics and response
to therapy prediction. Among thousands of genes predicted in the human genome, nearly half of them remain uncharacterized.
Considerable attention in the last decade has focused on the well-characterized known genes. However, the
future of cancer target discovery resides in the uncharacterized or novel genes called the dark matter of the human genome.
Realizing the importance of this vast untapped potential, recently the US National Cancer Institute announced a
new initiative called "Illuminating the Dark Matter of the Genome for Druggability". This area of cancer research albeit
exciting, remains a challenge due to the lack of adequate information about the uncharacterized genes. Amongst the plethora
of bioinformatics tools and databases, a streamlined approach remains elusive. In this review, we present a simplified
approach to mine directly the cancer proteome for rapid target discovery. Using such an approach, we have created a database
of uncharacterized cancer genes and have shown the biomarker and drug target potential for an uncharacterized
protein, C1ORF87, as a putative solid tumor target. In view of this protein's association with carcinomas, the C1ORF87 is
termed as Carcinoma-Related EF-Hand (CREF) gene. The approaches discussed in this review should aid in lighting the
dark matter of the human cancer proteome.
Keywords: Post genome, druggable genes, uncharacterized genes, C1ORF87, CREF gene.
Rights & PermissionsPrintExport